SynthesisNeurosurgical review2026
Facial nerve preservation following gamma knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2: a systematic review and meta-analysis of 552 tumors.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Retracted
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Facial nerve injury is a known possible complication in patients undergoing gamma knife radiosurgery (GKRS) for vestibular schwannoma (VS) in neurofibromatosis 2 (NF2). However there exists considerable heterogeneity in reported outcomes. Here we perform a systematic review of the literature and meta-analysis to evaluate the rate of facial nerve preservation across studies and to help identify predictive factors associated with facial nerve neuropathy in patients undergoing GKRS for NF2-associated VS. A systematic review was conducted on PubMed to assess all studies related to facial nerve preservation following GKRS for VS in patients with NF2 until November 2024. Meta-analysis was performed using SPSS version 20 (IBM Corp.). A total of 10 studies with 552 tumors and 405 patients were included in the analysis. The mean age of patients was 32 years. The mean tumor volume ranged from 1.5 cm3 to 15 cm3 and the mean median marginal dose of radiation used was 12.6 Gy. Facial nerve function was preserved after GKRS for 502/552 tumors (91%, 95% CI 83%—98%, p < 0.001) over mean durations ranging from 26.6 to 91.2 months. Mean Median Marginal dose had a significant moderate correlation with facial nerve preservation rates (r = -0.71, p = 0.01). GKRS has demonstrated superior facial nerve preservation rates in comparison to microsurgical resection as per historical data, affirming its accurate role in maintaining facial function. Although a dose of < 13 Gy could achieve higher preservation rates, larger future studies are warranted to identify the cut off for marginal doses and direct comparative studies between surgical and GKRS cohorts.
Indexed as
Identifiers
41653336What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.